The company will consolidate its manufacturing activities in Kvistgaard, Denmark with the aim of optimizing productivity and profitability.

As part of this consolidation, the company will prepare the Kvistgaard facility for the future commercial production of its prostate cancer vaccine, PROSTVAC and also transfer its production of clinical trial material to the facility. Consequently, the company will close its operations in Berlin, Germany, where it has been producing clinical trial material for its MVA-BN based vaccine candidates.